Metadherin promotes stem cell phenotypes and correlated with immune infiltration in hepatocellular carcinoma

Table 1 Description of the datasets used in this study

Clinical characteristics	GSE14520		TCGA
	Total (n = 210)	%	Total (n = 369)	%
Age
< 60	169	80.48	168	45.53
≥ 60	41	19.52	200	54.20
Unknown	–	–	1	0.27
Gender
Female	26	12.38	120	32.52
Male	184	87.62	249	67.48
T stage
T1	–	–	179	48.51
T2	–	–	94	25.47
T3	–	–	80	21.68
T4	–	–	13	3.52
Unknown	–		3	0.81
N stage
N0	–	–	250	67.75
N1	–	–	4	1.08
Nx	–		114	30.89
Unknown	–	–	1	0.27
M stage
M0	–	–	264	71.55
M1	–	–	4	1.08
Mx	–	–	101	27.37
Stage
I	90	42.86	169	45.80
II	75	35.71	86	23.31
III	43	20.48	85	23.04
IV	0	0.00	5	1.36
Unknown	2	0.95	24	6.50
Status
Alive	130	61.90	241	65.31
Dead	80	38.10	128	34.69
Unknown	–	–	0	0.00
HBV status
AVR-CC	52	24.76	–	–
CC	152	72.38	–	–
Unknown	6	2.86	–	–

HBV: Hepatitis B virus; AVR: Active viral replication chronic carrier; CC: Chronic carrier.

Table 2 Primers used in this study

Gene	Forward	Reverse
Metadherin	5′-CCAGGCTCCTTCATCAACTT-3′	5′-AthAAGCAGCCACCAGAGATTG-3′
CD133	5′-TGGATGCAGACCTTGACAACGT-3′	5′-ATACCTGCTACGACAGTCGTGGT-3′
Nanog	5′-AATACCTCAGCCTCCAGCAGATG-3′	5′- TGCGTCACACCATTGCTATTCTTC -3′
Oct4	5′-CAGGAGGCATTGCTGATGAT-3′	5′-GAAGGCTGGGGCTCATTT-3′
GAPDH	5′-CAGGAGGCATTGCTGATGAT-3′	5′- GAAGGCTGGGGCTCATTT -3′